FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The new test has been devised to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with ...

Penn State women’s volleyball coach Katie Schumacher-Cawley will receive the Jimmy V Award for Perseverance at Wednesday’s ...

In the early 2000s Modi helped to conduct a trial of T-DM1—branded Kadcyla by its maker, Genentech—in people who had an especially difficult disease: advanced HER2-positive breast cancer that ...